Update on the management of inflammatory bowel disease: specific role of adalimumab by Guidi, Luisa et al.
© 2011 Guidi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical and Experimental Gastroenterology 2011:4 163–172
Clinical and Experimental Gastroenterology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
163
REviEw
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CEG.S14558
Update on the management of inflammatory 
bowel disease: specific role of adalimumab
Luisa Guidi
Daniela Pugliese
Alessandro Armuzzi
internal Medicine and 
Gastroenterology, Complesso 
integrato Columbus, Università 
Cattolica del Sacro Cuore, Rome, italy
Correspondence: Luisa Guidi 
UO Medicina interna e Gastroenterologia, 
Complesso integrato Columbus,  
via Moscati 31, 00168 Roma, italy 
Tel +39 63503239 
Fax +39 63054641 
Email lguidi@rm.unicatt.it
Abstract: Anti-tumor necrosis factor alpha (TNF-α) medications are a class of biologics 
employed in the treatment of patients with inflammatory bowel disease (IBD). Adalimumab 
is the first fully human monoclonal immunoglobulin directed against TNF-α, which binds 
with high affinity and specificity to membrane and soluble TNF. Adalimumab administered 
subcutaneously has demonstrated efficacy in the treatment of rheumatoid arthritis, ankylosing 
spondylitis,   psoriatic arthritis, and severe chronic psoriasis. Studies have shown that adalimumab 
is effective for inducing and maintaining remission of moderate-to-severe active Crohn’s disease 
(CD) patients at an induction dose of 160/80 mg (week 0 and 2) and at a maintenance dose of 
40 mg every other week. The efficacy of adalimumab as a second-line therapy has also been 
documented for patients with loss of response or intolerance to infliximab. Adalimumab is also 
superior to placebo for inducing and maintaining complete perianal fistula closure. It also seems 
effective for reducing extraintestinal manifestations. The safety profile is similar to that of other 
anti-TNF therapy in CD patients, with lower immunogenicity and rate of adverse injection 
reactions than infliximab. Adalimumab is not approved for the treatment of ulcerative colitis 
(UC). Recently, however, the results of the first randomized, controlled trial on adalimumab for 
UC showed that adalimumab at 160/80 mg induction dose was safe and effective for inducing 
remission and clinical response after 8 weeks in patients with moderately-to-severely active 
UC failing treatment with corticosteroids and/or immunosuppressants. More data are necessary 
to clarify the therapeutic role of adalimumab in UC. This review of the literature summarizes 
available data on the efficacy and safety profile adalimumab in patients with IBD.
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Introduction
Inflammatory bowel diseases (IBD) are lifelong intestinal inflammatory   conditions 
of unknown etiology, characterized by remissions and exacerbations. The main 
  phenotypes of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). Their 
  pathogenesis is not totally understood, but in both diseases, bowel damage is induced 
by an uncontrolled activation of both innate and adaptive immunity due to an 
  inappropriate immune response to luminal antigens. This mechanism results in an 
imbalance between pro-inflammatory cytokines – interferon gamma (IFN-γ), tumor 
necrosis factor alpha (TNF-α), interleukin-1 (IL-1), IL-12 – and anti-inflammatory 
  mediators, which   maintains chronic tissue damage. TNF-α, produced by macrophages 
and activated T cells, plays a key role inducing further stimulation and recruitment 
of other   inflammatory cells.1Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Treatment decisions for IBD are typically based on 
  disease severity (mild, moderate, and severe) and   extension. 
Over recent years, the management of IBD has dramati-
cally changed. In particular, advances in understanding 
the pathogenesis and the natural course of the disease 
have substantially changed the therapeutic algorithms with 
the introduction of new biological drugs. Among these the 
anti-TNF-α monoclonal antibodies infliximab and adali-
mumab are currently approved for the management of CD, 
in particular for patients with moderately and severely active 
luminal disease who are nonresponders to conventional 
therapy. A third anti-TNF-α agent, certolizumab pegol, is 
approved for CD only in the US, Switzerland, and Russia. 
Infliximab and adalimumab are also indicated in the setting 
of surgical procedures as the first-choice medical therapy 
for complex perianal CD.2,3 At present only infliximab is 
approved for UC and is recommended for patients with 
moderate and severe UC refractory to corticosteroids and/
or immunomodulators.4,5 Adalimumab is a fully human 
anti-TNF-α monoclonal antibody and consists of human-
derived heavy- and light-chain variable regions and human 
IgG1 constant region. Adalimumab binds specifically to 
TNF-α and blocks its interaction with the p55 and p75 cell 
surface TNF receptors. It also lyses surface TNF-expressing 
cells in vitro in the presence of complement, but does not 
bind or inactivate lymphotoxin (TNF-β). It is administered 
subcutaneously (allowing home-based care) with induction 
dosing of 160 mg followed by 80 mg 2 weeks later (mean 
serum adalimumab trough concentrations of approximately 
12 µg/mL at week 2 and week 4). Subsequent maintenance 
dosing is of 40 mg every other week (eow). The pharmacoki-
netics of adalimumab were linear over the dose range of 0.5 
to 10.0 mg/kg following a single intravenous dose.6
Adalimumab in Crohn’s disease
Luminal CD
In the CLASSIC 1 trial (a 4-week multicenter, ran-
domized, placebo-controlled study), 299 patients with 
moderate-to-  severe active luminal CD, naïve to anti-TNF-α, 
received induction therapy with adalimumab 40 mg/20 mg, 
80 mg/40 mg, 160 mg/80 mg, or placebo, at weeks 0 and 2. 
The primary endpoint was remission at week 4 defined by a 
CD activity index (CDAI) ,150. At week 4, the remission 
rate was significantly higher in the 160/80 mg adalimumab 
group compared with placebo (36% vs 12%, P , 0.001). 
Clinical response (defined as a reduction of 70 points in the 
CDAI) was demonstrated in both higher dose adalimumab 
arms (80/40 mg: 59%, P , 0.05; 160/80 mg 59%, P , 0.01 
vs placebo 37%).7 At week 4, from the same cohort, 276 
patients in clinical remission (CDAI , 150 points) were 
enrolled in the CLASSIC 2 trial.8 After 4 open-label weeks 
of administration of adalimumab eow, 55 patients in   clinical 
remission were re-randomized to receive blinded adalimumab 
maintenance treatment with 40 mg eow or 40 mg weekly or 
placebo for 56 weeks. Patients who were not in clinical remis-
sion continued open-label adalimumab eow, with the option 
of increasing their dosage in case of flare or nonresponse. 
In the randomized arm, patients who experienced flares or 
nonresponse could switch to the open-label adalimumab eow 
arm. Remission rates were significantly higher for both the 
active arms than for placebo (40 mg eow: 79% 15/19 patients, 
40 mg weekly: 83% 15/18 vs placebo: 44% 8/18, P , 0.05). 
Patients who received either dosage of adalimumab also had 
a numerically greater rate of clinical response (reduction of 
100 and 70 points in the CDAI score) compared with patients 
who received placebo. In the open-label arm, 46% patients 
achieved remission at 56 weeks. The rates of serious adverse 
events were low in patients treated with adalimumab and were 
similar to placebo. Data from the CHARM trial,9 conducted 
in CD patients with the same clinical characteristics, support 
in a larger cohort (854 patients) the efficacy of adalimumab 
over placebo for maintaining clinical remission at 26 and 
56 weeks. In this trial, patients, after an open-label induction 
regimen of adalimumab 80/40 mg, were randomized at week 4 
to receive adalimumab 40 mg eow, 40 mg weekly, or placebo. 
Patients who experienced a disease flare (increase in CDAI 
of $70 points vs week 4 and an absolute CDAI score . 220) 
or sustained nonresponse (those who did not attain a decrease 
in CDAI of $70 points vs   baseline) at week 12 were   
subsequently permitted to switch to open-label adalimumab 
40 mg eow therapy. Open-label adalimumab patients with con-
tinued nonresponse or flares with 40 mg eow could switch 
to 40 mg weekly. Remission rates were significantly higher 
for both the active arms than for placebo at week 26 (40 mg 
eow: 40%, 40 mg weekly: 47% vs placebo: 17%, P , 0.001) 
and week 56 (36% and 41%, vs 12% placebo, P , 0.001). 
The proportion of patients in remission was significantly 
different between the active arms and placebo since week 
6 and through week 56. No significant differences were 
found between the dosage of 40 mg eow and 40 mg weekly. 
  Concomitant   immunomodulators or previous anti-TNF ther-
apy did not affect response, remission, or steroid withdrawal. 
However, among patients without concomitant immunosup-
pressants, the group treated with weekly adalimumab injec-
tions had 50% remission rate vs 33% eow, but this difference 
was not significant. Among all randomized patients 35% Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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withdrew before the end of treatment and 50% moved to 
unblinded adalimumab eow. The subgroup analysis showed 
that adalimumab was superior to placebo for maintaining a 
steroid-free clinical remission at 26 (adalimumab 40 mg eow 
35%, 40 mg weekly 30% vs placebo 6%, P , 0.001 for each 
adalimumab group) and 56 weeks (adalimumab 40 mg eow 
29%, 40 mg weekly 23% vs placebo 3%, P , 0.001 only for 
adalimumab eow). Hospitalization risks for all and CD-related 
causes were also higher for patients who received placebo 
compared with adalimumab. Fewer CD-related   surgeries 
occurred in the adalimumab groups (eow, weekly, and com-
bined groups) compared with placebo (0.4, 0.8, and 0.6 vs 
3.8 per 100 patients; all P , 0.05).10 Post hoc intention-to-
treat analysis, including all patients randomized regardless of 
whether they switched to the open-label arm, revealed also 
that continuous therapy with adalimumab was superior for 
inducing clinical remission compared with induction only or 
restart in case of flare (51% eow and 49% weekly, vs 38%, 
P , 0.05). The combined continuous adalimumab treatment 
group had also a 52% reduction in the number of surgeries 
(P , 0.01), fewer flares, and less risk of hospitalizations 
than the   induction/re-initiation group (P , 0.05).11 Of the 
260 patients initially randomized to adalimumab eow, 46% 
switched to open-label treatment because they experienced 
flares or lack of response. Among these, 19% moved to open-
label eow therapy and 27% moved to open-label weekly. From 
a regression model evaluating baseline characteristics, the 
CDAI score was the only statistically significant predictor of 
dose escalation, with a 72% greater risk for weekly dosing 
when baseline CDAI increases by 100 points.12 At 56 weeks, 
467 patients who completed the CHARM study entered the 
extension open-label study (ADHERE). All blinded patients 
received adalimumab eow, while patients who had already 
moved to open-label adalimumab eow or weekly continued 
their regimens upon entry in ADHERE. After up to 2 years 
of therapy, 37.6%, 41.9%, and 49.8% of patients originally 
randomized to placebo, adalimumab eow, and adalimumab 
weekly, respectively, were in clinical remission. All groups 
experienced sustained improvements in health-related 
quality life (measured with Inflammatory Bowel Disease 
  Questionnaire [IBDQ]).13
In the large cohort of the open-label CARE study, 945 
patients received 160/80 mg adalimumab at week 0–2 and 
then 40 mg eow. The percentage of patients in remission in 
the adalimumab group at week 4 was 43% and increased 
to 52% at week 20. From the same cohort, among the 497 
patients with baseline extraintestinal manifestation, 51% of 
patients were free of symptoms and signs at week 20.14
Recently, data from a systematic review on the loss of 
response and need for adalimumab dose intensification in 
adult and pediatric CD were published. Thirty-nine studies 
were included. The mean percentage of patients who lost 
response to adalimumab was 18.2% among a total of 955 
primary responders, with a calculated annual risk of 20.3% 
per patient-year. The mean percentage of patients who needed 
an adalimumab dose escalation was 21.4% and the annual 
risk was 24.4% per patient-year. Adalimumab dose escalation 
permitted response to be regained in 71.4% and remission 
in 39.9% of patients. Several predictors for loss of response 
were identified, but only previous treatment with anti-TNF 
therapy was confirmed in multiple studies.15
The results from the described randomized, controlled 
trials (RCT) are summarized in Table 1.
Perianal fistulizing CD
A post hoc analysis of the CHARM trial, on the efficacy 
in healing of draining perianal fistulas, has shown that 
adalimumab induced a reduction in the mean number of 
  draining fistulas per day compared with placebo (0.88 vs 
1.34, P , 0.002) during the 1-year double-blind treatment 
period. About 90% of patients who healed fistulas at the end 
of the CHARM trial maintained long-term fistula healing 
on 1 year of open-label therapy.16 In the open-label single 
arm CHOICE trial, 673 CD patients, who were infliximab 
primary nonresponders (17%) or initial responders (83%), 
were enrolled and treated with adalimumab (induction dose 
of 160/80 mg respectively at week 0 and 2, maintenance 
dose 40 mg eow) after a minimum of 8 weeks of infliximab 
washout period. At baseline, 88 patients (13%) had at least 
one draining cutaneous fistula. Complete fistula healing was 
achieved by 34 patients (39%) at the last visit (dates ranged 
from week 4 to week 36). In particular, 29.4% (10 of 34) 
completed week 12 and 64.7% (22 of 34) completed week 24 
or week 36. Improvements in quality of life and work produc-
tivity were sustained from week 4 to week 24 for all patients, 
as well as the subgroup of primary nonresponders.17
CD patients with primary or secondary 
nonresponse to infliximab
Sandborn et al, in the GAIN study, reported the first data 
on adalimumab use in infliximab intolerant or secondary 
nonresponder patients.18 In this 4-week trial, 325 patients 
with moderate-to-severe active CD (CDAI 220 to 450 
points) were randomized to receive blinded 160/80 mg 
adalimumab at week 0 and 2 or placebo. Patients were clas-
sified as: “having loss of response”, if they had received Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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at least 2 doses of infliximab and after an initial response, 
they lacked improvement, or had clinical worsening at least 
2 weeks after the last dose of infliximab; “intolerant”, if they 
had an acute adverse reaction or delayed infusion reaction. 
At 4 weeks, adalimumab induced higher rates of remis-
sion compared with placebo (21% vs 7%, P , 0.001). The 
improvements in CDAI by 70–100 points were also higher 
in the adalimumab arm. Patients in the adalimumab arm 
had statistically significantly lower mean CDAI total scores 
at week 1, 2, and 4 than did patients in the placebo group. 
At the end, patients who completed this trial were able to 
continue in the open-label extension and receive adalimumab 
40 mg eow. Remission rate was 39% at 6 months and 29% 
at 1 year.19 Data on the efficacy of adalimumab in primary 
nonresponders to infliximab are limited. Among the 945 
patients of the open-label cohort (OLC) of the CARE study, 
about one-quarter of patients were primary nonresponders 
to infliximab. Remission rate was significantly different 
between infliximab-naive and   infliximab-exposed patients 
(62% vs 42%, P , 0.001). No significant differences in 
remission rates were found between   primary nonresponders 
and intolerant patients or patients   having loss of response.14 
A systematic review including all the OLC and RCT was per-
formed by Ma et al,20 evaluating the efficacy of adalimumab 
in infliximab primary or secondary nonresponders. From the 
15 studies (2 RCT and 13 OLC) included, 1810 CD patients 
with previous infliximab were identified. Short-term clinical 
response at 4 weeks ranged from 41% to 83%. Long-term 
clinical remission at 12 months ranged from 19% to 68%. 
The authors concluded that the observed variability was due 
to differences in the study design and baseline characteristics 
of patients included in the studies.
Table 1 Randomized controlled trials on adalimumab in Crohn’s disease
No. of patients Treatment Primary outcomes
Hanauer et al7 299  
induction:
  40 mg/20 mg week 0–2
  80 mg/40 mg week 0–2
  160 mg/80 mg week 0–2
  Placebo week 0–2
week 4% (P vs placebo)
Remission rate
18 (0.36)
24 (0.06)
36 (0.001)
12
Sandborn et al8 276  
55a maintenance:
  40 mg eow for 56 weeks
  40 mg weekly for 56 weeks
  Placebo
week 56% (P vs placebo)
Remission rate
79 (0.05)
83 (0.05)
44
Colombel et al9 854 778b maintenance:
  40 mg eow for 56 weeks
  40 mg weekly for 56 weeks
  Placebo
week 26% (P vs placebo)  
40 (0.001) 
47 (0.001) 
17
week 56% (P vs placebo)
36 (0.001)
41 (0.001)
12
Colombel et al16 117 117c maintenance:
  40 mg eow for 56 weeks
  40 mg weekly for 56 weeks
  Both adalimumab group for 56 weeks
  Placebo
Week 56 mean number of draining fistula
0.85
0.91
0.88 (P , 0.002 vs placebo)
1.34
Sandborn et al18 325  
induction:
  160 mg/80 mg week 0–2
  Placebo
week 4% (P vs placebo)
Remission rate
21 (P , 0.001)
7
Colombel et al21 135  
129d maintenance:
  40 mg eow
  Placebo
week 12
Remission rate % 
16 (0.34) 
10
week 52
(P vs placebo)
19
0
Hyams et al25 192 188e maintenance for 48 weeks:
    High dose (40 mg eow Bw . 40 kg,  
20 mg eow Bw < 40 kg)
    Low dose (20 mg eow Bw . 40 kg, 
10 mg eow Bw < 40 kg)
Clinical remission week 26
High dose 39% vs low dose 28% (P = 0.075)
Notes: ain remission at week 0 and 2 after 2 open-label 40 mg adalimumab doses; bafter an open-label induction 80/40 mg at week 0 and 2; cpatients with draining fistula at 
baseline in the cohort of the CHARM trial; dafter an open-label induction 160/80 mg at week 0–2; eafter an open-label adalimumab induction per body-weight (160 mg/80 mg 
week 0–2 if body weight . 40 kg, 80 mg/40 mg week 0–2 if body weight , 40 kg).
Abbreviation: eow, every other week.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Mucosal healing
Colombel et al recently presented data from the EXTEND 
study (the available data are limited, because only the abstract 
is available).21 In this randomized placebo-controlled study, 
135 patients with moderate-to-severe ileocolonic CD (CDAI, 
220–450) and baseline mucosal ulceration (score of 2 or 3 
for $1 colon segment in the ulcerated surface subscore of 
the Simple Endoscopic Score for Crohn’s disease) were 
enrolled. After an open-label adalimumab induction therapy 
with 160 mg at week 0 and 80 mg at week 2, 129 patients 
were randomized to maintenance therapy with adalimumab 
40 mg eow or placebo. Patients who had flares or did not 
respond could receive open-label adalimumab from week 8. 
The   primary endpoint was deep remission, defined as   clinical 
remission with CDAI of ,150, plus mucosal healing, as evi-
denced by the absence of mucosal ulceration at week 12 and 
52. At week 12, more patients in the adalimumab group (16%) 
than in the induction-only placebo group (10%) had achieved 
both clinical remission and mucosal healing, although the dif-
ference was not statistically significant (P = 0.34). At week 
52, however, there was a highly   significant difference between 
the two groups (19% vs 0% for adalimumab and placebo, 
respectively; P , 0.001). Post hoc analysis revealed that early 
deep remission predicts   better long-term outcomes.22 Patients 
with early deep remission were about five times more likely 
to achieve both IBDQ remission and a normal SF-36 physical 
(PCS) score (both P , 0.05) at week 52.
Pediatric CD
The RESEAT study is a large multicenter experience using 
adalimumab for pediatric CD.23 In this retrospective study, 
data on 115 children, treated with adalimumab are reported. 
Overall, 65% of all subjects had moderate-to-severe disease 
activity at baseline by physician global assessment (PGA), 
whereas 21% had mild disease and 15% were inactive. Mean 
age at the time of diagnosis of CD was 11.1 ± 3.1 years and 
the first dose of adalimumab was administered at a mean 
age of 15.8 ± 3.0 years, which was equivalent to a mean of 
4.7 ± 2.8 years (range 0.3–14.7 years) after diagnosis. Only 
5% (6) of patients were naïve to infliximab. Reasons for the 
discontinuation of infliximab therapy included secondary loss 
of response to the agent in 51 patients (47%), infusion reaction 
or delayed hypersensitivity in 49 (45%), and preference for an 
injectable agent in ten patients (9%). The clinical response rates 
at 3, 6, and 12 months after the start of adalimumab therapy 
were 65%, 71%, and 70%, measured with PGA (clinical 
response was defined as a decrease in the PGA from either 
moderate or severe to mild/inactive or from mild to inactive). 
Clinical remission (improvement in PGA to inactive) was 
32%, 43%, and 49%, at 3, 6, and 12 months, respectively. 
There were no malignancies, serious infections, or deaths in 
the study subjects. Recently, Russell et al reported data of a 
multicenter English cohort of 70 CD children with a median 
age of 14.8 years and a median duration of disease of 4.3 years 
at start of adalimumab treatment. Among these, 91% had prior 
thiopurines and 94% had prior infliximab usage. Remission 
rates were 24%, 58%, and 41% at 1, 6, and 12 months, 
respectively, with higher rate of remission in the subgroup of 
patients on concomitant immunosoppression with thiopurine 
or methotrexate (34/46 [74%] vs 9/24 [37%], P = 0.003). In this 
cohort, 15 adverse events were recorded and four of these 
were serious (6%), including one severe case of Clostridium 
difficile infection, one case of stomal abscess with subsequent 
fistulization, and two deaths due to sepsis (3% mortality rate). 
Both the patients who died were receiving adalimumab plus 
concomitant immunosuppressive drugs and parenteral nutri-
tion.24 Recently, data on the first randomized, double-blind trial 
on the use of adalimumab in children were reported.25 In this 
study, 192 children, after an open-label induction per body 
weight (160 mg/80 mg week 0–2 if body weight . 40 kg, 
80 mg/40 mg week 0–2 if body weight , 40 kg), stratified for 
previous infliximab exposure and for week 4 response, were 
randomized at week 4 to receive adalimumab maintenance 
therapy at high dose (40 mg eow if body weight . 40 kg or 
20 mg eow if body weight , 40 kg) or at low dose (20 mg eow 
if body weight . 40 kg or 10 mg eow if body weight , 40 kg) 
for 48 weeks. At week 26, a higher proportion in the high-dose 
group achieved clinical remission than in the low-dose group 
(39% vs 28%, P = 0.075), with a significant difference between 
Infliximab naïve patients (P = 0.026) and those with clinical 
response at week 4 (P = 0.016).
Adalimumab in ulcerative colitis
Adalimumab is not approved to treat UC patients. The first 
evidence for the efficacy of adalimumab in UC, from open-
label trials26–30 and retrospective studies,31,32 revealed that 
adalimumab could be an effective therapeutic option for 
inducing and maintaining remission in patients with active 
UC intolerant or refractory to standard therapy.
However, the results of a double-blind RCT were recently 
published. It was an 8-week multicenter study, conducted 
in North America and Europe and included patients with 
moderately-to-severely active UC (full Mayo score of 6–12, 
with endoscopic subscore of 2–3).33 All patients were naïve 
to anti-TNF and failed or did not tolerate standard treat-
ments with corticosteroids or immunomodulators. Initially Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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186 patients were enrolled and randomized to subcutaneous 
treatment with an induction dose of 160/80 mg or placebo. 
Subsequently, after an amendment (number 3) to the proto-
col, a third arm receiving adalimumab at induction dose of 
80/40 mg was included. Primary endpoint was clinical remis-
sion at week 8 (full Mayo Score # 2).   Secondary endpoints 
were clinical response, mucosal healing, and improvement in 
rectal bleeding, PGA, and decrease in stool frequency at week 
8. At week 8, the proportion of patients in clinical remission in 
the adalimumab 160/80 mg group was 18.5% compared with 
9.2% of the placebo group (P = 0.031) with a therapeutic gain 
of adalimumab over placebo of 9.3%. No difference was found 
between the adalimumab 80/40 mg group (10% remission rate) 
and placebo group (P = 0.833). There was a higher proportion 
of patients with subscores of mild   disease in the adalimumab 
160/80 mg group compared with placebo, with significant 
differences for the rectal bleeding subscore (P = 0.038) and 
PGA (P = 0.035). No significant differences were found in 
terms of clinical response and mucosal healing between the 
three arms. In particular the clinical response was obtained 
in 44.6% of patients in the placebo arm, in 51.5% of patients 
in the adalimumab 80/40 arm, and in 54.6% of patients in the 
adalimumab 160/80 arm. The mucosal healing was scored in 
41.5% of patients in the placebo arm, in 37.7% of patients in 
the adalimumab 80/40 arm, and in 54.6% of patients in the 
adalimumab 160/80 arm. The additional post hoc analyses 
showed that extensive disease, more active disease, and high 
levels of C-reactive protein (CRP = 10 mg/L) were associated 
with low rates of clinical remission, which possibly reflects a 
greater efficacy of adalimumab in less severe disease. In the 
subgroup of patients who weighed . 82 kg, remission rate was 
lower than in patients who weighed , 70 kg, especially in the 
adalimumab 160/80 mg group (9.6% vs 24.4%, respectively). 
After 8 weeks, 390 patients (originally randomized to all 3 
arms) entered an open-label extension to receive   adalimumab 
40 mg eow as maintenance therapy through 52 weeks. In 
case of flare or nonresponse, the dose could be increased 
to weekly. At 52 weeks, 25.6% of patients were in clinical 
remission with maintenance therapy of 40 mg eow (dose 
escalation considered as failure). From a post hoc analysis, 
not taking into account patients who dose escalated as failures, 
remission rate at 52 weeks was 29.5%.34 The quality of life 
through 52 weeks, measured by IBDQ, has been improved 
by adalimumab maintenance therapy in UC.35
Recently, the results of an induction and maintenance 
study were presented.36 In this study 494 UC patients (Mayo 
score 6–12, endoscopic subscore 2–3 points) were random-
ized to placebo or adalimumab 160 mg at week 0, 80 mg at 
week 2, and then 40 mg eow starting on week 4. Co-primary 
endpoints were clinical remission at week 8 and clinical 
remission at week 52. Significantly more adalimumab-treated 
patients achieved clinical remission at week 8 (16.55%, 
P = 0.02) and at week 52 (17.3%, P , 0.01) compared with 
placebo (9.3% at week 8 and 8.5% at week 52).   Adalimumab 
was efficacious in inducing and maintaining clinical remis-
sion in patients with moderate-to-severe UC who did not 
respond adequately to conventional therapy with oral 
corticosteroids/immunosuppressants.
The results from the described RCTs are summarized 
in Table 2.
Safety
Because adalimumab is administered subcutaneously, 
the injection site reactions are generally mild and do not 
necessitate drug discontinuation.6 This is a major advance 
compared with infliximab, which is administered through 
an infusion, which could be complicated by acute adverse 
reactions, including mild to severe clinical manifestations 
and delayed hypersensitivity-like reactions. The safety pro-
file of adalimumab in global clinical trials in CD patients 
Table 2 Randomized controlled trials on adalimumab in ulcerative colitis
No. of patients Treatment Outcomes
Reinisch et al33 576 induction:
  160 mg/80 mg week 0–2
  Placebo week 0–2
  80 mg/40 mga week 0–2
Clinical remission
18.5 (0.031)
9.2 (0.833)
10
Sandborn et al36 494 induction:
  160 mg/80 mg week 0–2
  Placebo week 0–2
Maintenance:
  40 mg eow starting at week 4
  Placebo week 0–2
Clinical remission
% (P vs placebo) week 8
16.5 (0.02)
9.3
% (P vs placebo) week 52
17.3 (,0.01)
8.5
Note: aThis arm was included after amendment 3, adding a third arm of adalimumab at induction, with a dose of 80/40 mg.
Abbreviation: eow, every other week.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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was similar to that of other TNF antagonists in CD and the 
rates of adverse events were comparable to those of the other 
approved indications for adalimumab. Analyzing the larg-
est trial of adalimumab in CD, the types and frequency of 
adverse events, serious adverse events, and adverse events 
of interest were similar to placebo during both induction 
and maintenance periods and did not differ by dosing regi-
men used during induction or maintenance.37 No difference 
was found for serious infections between placebo and the 2 
adalimumab groups (40 mg eow and 40 mg weekly).7,8 Of 
172 patients in the CLASSIC 2 cohort with measurement 
at baseline and at 56 weeks and no antinuclear antibodies 
at baseline, 33 (19%) tested positive at their final visits and 
anti-ds-DNA antibodies were observed in all 33 patients 
at this time point. None of these patients developed novel 
clinical symptoms suggestive of autoimmunity.8 In the all-
exposed patients from the main trials, 56 patients (1.8%) 
had opportunistic infections. Oral candidiasis/thrush (37 
patients, 1.2%) was the most commonly reported oppor-
tunistic infection). The most frequently reported serious 
adverse event was serious infection (5.8%), most commonly 
abscess (intra-abdominal and gastrointestinal-related), fol-
lowed by gastrointestinal infections (excluding abscess), 
and pulmonary infections. Low incidences of malignancies 
were reported in the CD trials, in particular one lymphoma 
(0.07/100 patients year). Lupus-related disorders and 
demyelinating disorders, although uncommon, occurred 
in adalimumab-treated patients with CD. Four deaths were 
recorded; in particular only one of these was related to 
adalimumab therapy (one case of acute myeloid leukemia).37 
As with all other anti-TNF-α drugs having an impact on 
cell-mediated immunity, there is a warning on the emerg-
ing infections sustained by intracellular pathogens (such 
as tuberculosis, listeriosis, and histoplasmosis). Therefore, 
screening for latent tuberculosis should be performed before 
starting adalimumab therapy (anamnesis, chest Rx, PPD 
skin test, IGRA test). Patients treated with anti-TNF-α 
have also an increased risk of viral infection, in particular 
of reactivation of chronic or latent infection. The hepatitis 
B virus and herpes family virus (HSV, EBV, CMV, VZS) 
are the most frequently involved, so it is very important to 
screen patients before starting therapy and to recognize any 
clinical manifestation. For patients with latent HBV infec-
tion, prophylaxis with lamivudine is recommended during 
anti-TNF-α therapy.38
Data on safety of adalimumab in UC patients are limited. 
No deaths or malignancies have been reported. In the induc-
tion RCT,33 serious adverse events occurred in 7.6%, 3.8%, 
and 4.0% of patients in the placebo, adalimumab 80/40 mg, 
and adalimumab 160/80 mg groups, respectively. In the study 
by Afif et al,28 serious adverse events were reported in six 
out of 20 patients, none of which were judged as probably 
related to the administration of adalimumab. Therefore the 
safety profile seems to be similar to the experience with this 
drug in CD.
As reported in a multicenter Italian cohort of IBD patients 
treated with biological drugs, patients older than 65 years 
have a higher rate of severe infections and mortality than 
younger patients or patients of the same age who did not 
receive these therapeutics.39
Finally, an emerging and increasing paradoxical col-
lateral effect of anti-TNF-α drugs is psoriasis. Many cases 
have been reported of new-onset of palmo-plantar psoriasis 
occurring in the course of treatment from days to years after 
drug initiation, most of which resolve after cessation of the 
drugs or in some cases after switching to other anti-TNF-α. 
The treatment (topical or systemic therapy) is based on toler-
ance of patients and extension of lesions.40
immunogenicity
The fully human “designed” features of adalimumab do not 
eliminate the risk of antidrug antibodies. In fact, differences 
in amino acid sequences or glycoprotein content could 
induce an activation of adaptive immunity with production 
of human–antihuman antibodies (HAHA). In the CLASSIC 
2 study8 the percentage of patients developing antibodies to 
the human antibody adalimumab was low (7/269, 2.6%), all 
in the 185 patients without concomitant immunosuppres-
sion (3.8%). Data on correlation between the presence of 
anti-adalimumab antibodies and adverse events are lacking. 
However, the long-term outcome of adalimumab therapy 
seems to be influenced by the presence of HAHA and 
the trough serum levels. Data from the cohort of Leuven 
  University Hospital (168 CD patients, who previously failed 
infliximab) showed that low trough serum concentrations 
of adalimumab were associated with increased early and 
late discontinuation rates. HAHA were detected in 9.2% 
of the 92% of patients with trough serum concentration 
below the threshold for detection at least once during the 
follow-up, which may be responsible for rapid elimination 
of adalimumab and loss of response. However, there was 
no direct relationship between trough serum concentration 
and short-term efficacy of treatment. Concomitant immu-
nomodulator therapy did not influence treatment outcome, 
adalimumab trough serum concentration, rate of adverse 
events, or development of HAHA.41 On the other hand, the 
chimeric features of infliximab (75% human and 25% murine 
sequence) are correlated with development of antibodies to Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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infliximab, which may also be a mechanism underlying the 
secondary loss of response to infliximab.
Pregnancy and breast feeding
Adalimumab is classified as pregnancy category B drug by 
the US Food and Drug Administration, which means that 
either animal studies have not demonstrated a fetal risk 
but there are no controlled studies in pregnant women, or 
  animal studies have shown an adverse effect that was not 
  confirmed in controlled studies in women in the first   trimester. 
  However, the recommendation to withdraw adalimumab 
before the third trimester, likewise infliximab, is arbitrary 
and based on the evidence that IgG1 passes the placental 
barrier   during the second and the third trimester. Little data 
exist on the diffusion of adalimumab across the placenta. In 
a recent study, which includes five pregnant women with IBD 
receiving adalimumab, levels of the drug were measured in 
the mother, infant, and cord blood on the day of the birth. 
In all cases, the cord blood level of adalimumab was higher 
than the maternal level, supporting active transfer from the 
mother to the infant. Adalimumab also was detectable in 
the infant blood for at least 3 months from birth.42 Few data 
have been published on safety of adalimumab in pregnancy, 
especially in IBD patients. A report from the Organization 
for Teratology Information Specialists on 33 women enrolled 
in a prospective study on adalimumab use in pregnancy has 
shown a 12.1% rate of spontaneous abortion and stillbirth, 
not significantly different from the 5.6% of the diseased 
controls and 4% in the general population. Also congenital 
malformations and preterm deliveries were in the range of 
the nondisease controls.43 Similar results come from a recent 
systematic review of the literature on anti-TNF-α use and 
fetal risk, in which 38 studies were included, for a total 
number of 437 women (189 infliximab, 230 adalimumab, 18 
certolizumab pegol). The rates of congenital abnormalities 
(3.4%), fetal deaths (8.5%), and preterm births (2.7%) were 
similar to the rates in the general population.44 Safety during 
breastfeeding is unknown, but little evidence is available on 
excretion of adalimumab in breast milk.45
Future perspectives
Evidence from published research supports the fact that early 
treatment with anti-TNF-α seems to be more effective than 
traditional therapy for inducing clinical benefits and endo-
scopic remission, especially in selected patients with features at 
diagnosis that suggest poor outcome (top-down strategy).46 At 
present, data on top-down strategies are not available for adali-
mumab. In addition, for infliximab, the combination therapy 
with azathioprine seems to be the most effective treatment for 
inducing steroid-free remission at 26 weeks.47 The first data 
on the comparison of the combination of adalimumab with 
azathioprine vs adalimumab as monotherapy are pending,48 
but larger randomized controlled trials are necessary.
Conclusion
The advent of biological agents has modified the paradigm of 
treatment of IBD, since they are effective for induction and 
maintenance of sustained corticosteroid-free remission and 
mucosal healing. The current guidelines recommend that 
anti-TNF-α therapies should be reserved for IBD patients 
in whom conventional therapies have failed, as second-line 
therapy. In particular in CD, all the three anti-TNF-α available 
are recommended, in combination with surgical therapy, for 
patients with moderately-to-severely active disease, who have 
previously been steroid-refractory, -dependent, or -intolerant 
and with perianal disease. Adalimumab is an effective therapy 
for inducing and maintaining remission in patients with active 
moderate-to-severe luminal CD, naïve to anti-TNF or with 
intolerance or loss of response to infliximab, and in perianal 
fistulizing patients. It is well tolerated and not associated to 
adverse acute or delayed reactions. In the main clinical trials 
the rates of adverse events were comparable with other anti-
TNF-α and to other approved indications for adalimumab. 
The rates of induced antidrug antibodies were lower than 
for infliximab and this phenomenon was not associated with 
adverse events or loss of response. At present, because of the 
lack of comparative trials with different anti-TNF-α in CD, 
the decisions of clinicians are often determined case by case 
and based on personal experiences, not on objective criteria. 
Subcutaneous administration may be preferred by many 
patients because it allows home-based care.
In UC patients, there is an increasing evidence that 
adalimumab could be effective for inducing and   maintaining 
remission, with variable action in different subsets of patients. 
Although the percentages of UC patients responding to 
adalimumab in the available studies are not outstanding, they 
are significantly higher than in the placebo groups. This is 
an important achievement, which will open the way for the 
use of a second anti-TNF-α agent in these patients, when for 
instance, the response to infliximab is lost or an infusion reac-
tion develops. Furthermore, direct comparison of responder 
rate is not feasible among studies employing different drugs, 
with different designs and selection criteria.
Further efforts should be made to improve our knowledge 
so that in future every IBD patient could be treated with the 
right drug at the right time.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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